Applied Genetic Technologies Corporation

Informe acción NasdaqGM:AGTC

Capitalización de mercado: US$12.6m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Applied Genetic Technologies Dirección

Dirección controles de criterios 1/4

Información clave

Sue Washer

Chief Executive Officer (CEO)

US$1.5m

Compensación total

Porcentaje del salario del CEO37.4%
Permanencia del CEO20.7yrs
Participación del CEO0.2%
Permanencia media de la dirección1.4yrs
Promedio de permanencia en la Junta Directiva11.3yrs

Actualizaciones recientes de la dirección

Recent updates

AGTC receives positive feedback from FDA for manufacturing facility

Jul 26

Applied Genetic Technologies proposes stock offering to fund clinical trials

Jul 12

Applied Genetic Tech: A Speculative Biotech With Potential To Turn Corner In 2022

Jan 12

An Assessment Of Applied Genetic Technologies Corporation

Dec 14

Applied Genetic Technologies: Weak Early Clinical Ocular Results Highlight Increased Risk

Jul 15

Is Applied Genetic Technologies (NASDAQ:AGTC) A Risky Investment?

May 21
Is Applied Genetic Technologies (NASDAQ:AGTC) A Risky Investment?

Applied Genetic trades lower after announcing the departure of chief scientific officer

Apr 26

What Is The Ownership Structure Like For Applied Genetic Technologies Corporation (NASDAQ:AGTC)?

Feb 05
What Is The Ownership Structure Like For Applied Genetic Technologies Corporation (NASDAQ:AGTC)?

Is Applied Genetic Technologies (NASDAQ:AGTC) Using Debt In A Risky Way?

Jan 06
Is Applied Genetic Technologies (NASDAQ:AGTC) Using Debt In A Risky Way?

What Type Of Returns Would Applied Genetic Technologies'(NASDAQ:AGTC) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Dec 11
What Type Of Returns Would Applied Genetic Technologies'(NASDAQ:AGTC) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Interim data on gene therapy for vision loss disorder fails to lift Applied Genetic

Nov 11

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Sue Washer en comparación con los beneficios de Applied Genetic Technologies?
FechaCompensación totalSalarioIngresos de la empresa
Sep 30 2022n/an/a

-US$70m

Jun 30 2022US$1mUS$551k

-US$69m

Mar 31 2022n/an/a

-US$63m

Dec 31 2021n/an/a

-US$63m

Sep 30 2021n/an/a

-US$60m

Jun 30 2021US$1mUS$530k

-US$58m

Mar 31 2021n/an/a

-US$60m

Dec 31 2020n/an/a

-US$57m

Sep 30 2020n/an/a

-US$50m

Jun 30 2020US$988kUS$530k

-US$46m

Mar 31 2020n/an/a

-US$42m

Dec 31 2019n/an/a

-US$19m

Sep 30 2019n/an/a

-US$15m

Jun 30 2019US$1mUS$514k

-US$2m

Mar 31 2019n/an/a

US$2m

Dec 31 2018n/an/a

-US$18m

Sep 30 2018n/an/a

-US$19m

Jun 30 2018US$1mUS$502k

-US$21m

Mar 31 2018n/an/a

-US$18m

Dec 31 2017n/an/a

-US$11m

Sep 30 2017n/an/a

-US$4m

Jun 30 2017US$1mUS$487k

US$407k

Mar 31 2017n/an/a

US$6m

Dec 31 2016n/an/a

US$10m

Sep 30 2016n/an/a

US$11m

Jun 30 2016US$2mUS$464k

-US$1m

Compensación vs. Mercado: Sue's total compensation ($USD1.47M) is above average for companies of similar size in the US market ($USD749.50K).

Compensación vs. Ingresos: Sue's compensation has increased whilst the company is unprofitable.

CEO

Sue Washer (61 yo)

20.7yrs

Permanencia

US$1,473,567

Compensación

Ms. Susan B. Washer, also known as Sue, has been the President and Chief Executive Officer of Applied Genetic Technologies Corporation since March 2002. Ms. Washer is an experienced entrepreneur with a str...

Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Susan Washer
President20.7yrsUS$1.47m0.21%
$ 26.7k
Jonathan Lieber
Chief Financial Officer1.2yrsUS$1.00msin datos
Susan Schneider
Chief Medical Officerless than a yearUS$832.63ksin datos
Nicholas Muzyczka
Co-Founder23.8yrssin datossin datos
Barry Byrne
Co-Founder23.8yrssin datossin datos
William Hauswirth
Co-Founder & Member of Ophthalmology Scientific Advisory Boardno datasin datossin datos
Richard Samulski
Co-Founder23.8yrssin datossin datos
Terence Flotte
Co-Founder23.8yrssin datossin datos
Gerald Reynolds
Chief Accounting Officer1.4yrssin datos0.013%
$ 1.6k
Abraham Scaria
Chief Scientific Officerless than a yearsin datossin datos
Hope D'Oyley-Gay
General Counselless than a yearsin datossin datos
David Knop
Senior Vice President of Process & Assay Developmentless than a yearUS$141.25ksin datos

1.4yrs

Permanencia media

57yo

Promedio de edad

Equipo directivo experimentado: AGTC's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.

Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Susan Washer
President19yrsUS$1.47m0.21%
$ 26.7k
William Hauswirth
Co-Founder & Member of Ophthalmology Scientific Advisory Boardno datasin datossin datos
Edward Hurwitz
Independent Director10yrsUS$65.23k0.041%
$ 5.1k
Anne VanLent
Independent Director6.3yrsUS$79.23ksin datos
Scott Koenig
Independent Chairman of the Board20.6yrsUS$101.50k0.051%
$ 6.4k
David Birch
Member of Ophthalmology Scientific Advisory Boardno datasin datossin datos
William Aliski
Independent Director4.2yrsUS$78.23k0.013%
$ 1.6k
Peter Campochiaro
Member of Ophthalmology Scientific Advisory Boardno datasin datossin datos
James Rosen
Independent Director12.7yrsUS$72.34k0.0015%
$ 186.7
Paul Kaufman
Member of Ophthalmology Scientific Advisory Boardno datasin datossin datos
Stephen Daiger
Member of Ophthalmology Scientific Advisory Boardno datasin datossin datos
Robert Molday
Member of Ophthalmology Scientific Advisory Boardno datasin datossin datos

11.3yrs

Permanencia media

65.5yo

Promedio de edad

Junta con experiencia: AGTC's board of directors are seasoned and experienced ( 11.3 years average tenure).